Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 46 AL 60

Molecular Targets of Tannic Acid in Alzheimer's Disease

Braidy N, Jugder BE, Poljak A, Jayasena T, Nabavi SM, Sachdev P, Grant R.

Curr Alzheimer Res. 2017;14(8):861-869. doi: 10.2174/1567205014666170206163158.

Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance

Quittot N, Sebastiao M, Bourgault S.

Biochem Cell Biol. 2017 Jun;95(3):329-337. doi: 10.1139/bcb-2016-0236. Epub 2017 Feb 1.

Alzheimer's disease in the zebrafish: where can we take it?

Caramillo EM, Echevarria DJ.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):179-186. doi: 10.1097/FBP.0000000000000284.

The contribution of transgenic and nontransgenic animal models in Alzheimer's disease drug research and development

Mhillaj E, Cuomo V, Mancuso C.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):95-111. doi: 10.1097/FBP.0000000000000296.

Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer's disease

Franco R, Martínez-Pinilla E, Navarro G, Zamarbide M.

Prog Neurobiol. 2017 Feb-Mar;149-150:21-38. doi: 10.1016/j.pneurobio.2017.01.004. Epub 2017 Feb 9.

The Methylenetetrahydrofolate Reductase C677T Polymorphism and Risk for Late-Onset Alzheimer's disease: Further Evidence in an Italian Multicenter Study

Stoccoro A, Tannorella P, Salluzzo MG, Ferri R, Romano C, Nacmias B, Siciliano G, Migliore L, Coppedè F.

J Alzheimers Dis. 2017;56(4):1451-1457. doi: 10.3233/JAD-161081.

Therapeutics of Neurotransmitters in Alzheimer's Disease

Kandimalla R, Reddy PH.

J Alzheimers Dis. 2017;57(4):1049-1069. doi: 10.3233/JAD-161118.

Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data

Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

Am J Geriatr Psychiatry. 2017 Jul;25(7):708-716. doi: 10.1016/j.jagp.2017.01.016. Epub 2017 Jan 30.

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study

Tai SY, Chen CH, Chien CY, Yang YH.

BMC Neurol. 2017 Feb 23;17(1):40. doi: 10.1186/s12883-017-0800-y.

Biophenols pharmacology against the amyloidogenic activity in Alzheimer's disease

Omar SH.

Biomed Pharmacother. 2017 May;89:396-413. doi: 10.1016/j.biopha.2017.02.051. Epub 2017 Feb 27.

Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!

Cardoso SM, Correia SC, Carvalho C, Moreira PI.

Handb Exp Pharmacol. 2017;240:281-308. doi: 10.1007/164_2017_3.

Alzheimer's disease pathology and the unfolded protein response: prospective pathways and therapeutic targets

Koss DJ, Platt B.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):161-178. doi: 10.1097/FBP.0000000000000299.

Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease

Calhoun A, Ko J, Grossberg GT.

Expert Opin Emerg Drugs. 2017 Mar;22(1):101-105. doi: 10.1080/14728214.2017.1293651.

Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer's Disease

Reddy AP, Reddy PH.

Prog Mol Biol Transl Sci. 2017;146:173-201. doi: 10.1016/bs.pmbts.2016.12.010. Epub 2017 Feb 11.

Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs

Caraci F, Sultana J, Drago F, Spina E.

CNS Neurol Disord Drug Targets. 2017;16(4):501-513. doi: 10.2174/1871527316666170303144817.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias